[1] Kodjikian L, Bellocq D, Bodaghi B. Management of Irvine-Gass syndrome. J Fr Ophtalmol, 2017; 40, 788−92. doi:  10.1016/j.jfo.2017.09.001
[2] Henderson BA, Kim JY, Ament CS, et al. Clinical pseudophakic cystoid macular edema: risk factors for development and duration after treatment. J Cataract Refract Surg, 2007; 33, 1550−8. doi:  10.1016/j.jcrs.2007.05.013
[3] Massa H, Georgoudis P, Panos GD. Dexamethasone intravitreal implant (OZURDEX®) for macular edema secondary to noninfectious uveitis: a review of the literature. Ther Deliv, 2019; 10, 343−51. doi:  10.4155/tde-2019-0024
[4] Gallego-Pinazo R, Castillo SM, Dolz-Marco R, et al. Analysis of prognostic factors by spectral - domain optical coherence tomography in pseudophakic cystoid macular oedema. Arch Soc Esp Oftalmol (Engl Ed), 2012; 87, 23−4. doi:  10.1016/j.oftal.2011.06.005
[5] Irvine SR. A newly defined vitreous syndrome following cataract surgery: interpreted according to recent concepts of the structure of the vitreous, the seventh Francis I. Proctor lecture. Am J Ophthalmol, 1953; 36, 599−600, 600a, b, 601-19.
[6] Gass JDM, Norton EWD. Cystoid macular edema and papilledema following cataract extraction: a fluorescein fundoscopic and angiographic study. 1966. Retina, 2003; 23, 646−61.
[7] Orski M, Gawęcki M. Current management options in Irvine-Gass syndrome: a systemized review. J Clin Med, 2021; 10, 4375. doi:  10.3390/jcm10194375
[8] Benitah NR, Arroyo JG. Pseudophakic cystoid macular edema. Int Ophthalmol Clin, 2010; 50, 139−53. doi:  10.1097/IIO.0b013e3181c551da
[9] Hunter AA, Modjtahedi SP, Long K, et al. Improving visual outcomes by preserving outer retina morphology in eyes with resolved pseudophakic cystoid macular edema. J Cataract Refract Surg, 2014; 40, 626−31. doi:  10.1016/j.jcrs.2013.09.018
[10] Bellocq D, Mathis T, Voirin N, et al. Incidence of Irvine Gass syndrome after phacoemulsification with spectral-domain optical coherence tomography. Ocul Immunol Inflamm, 2019; 27, 1224−31. doi:  10.1080/09273948.2019.1634215
[11] Guo SQ, Patel S, Baumrind B, et al. Management of pseudophakic cystoid macular edema. Surv Ophthalmol, 2015; 60, 123−37. doi:  10.1016/j.survophthal.2014.08.005
[12] Bellocq D, Korobelnik JF, Burillon C, et al. Effectiveness and safety of dexamethasone implants for post-surgical macular oedema including Irvine-Gass syndrome: the EPISODIC study. Br J Ophthalmol, 2015; 99, 979−83. doi:  10.1136/bjophthalmol-2014-306159
[13] Khurana RN, Palmer JD, Porco TC, et al. Dexamethasone intravitreal implant for pseudophakic cystoid macular edema in patients with diabetes. Ophthalmic Surg Lasers Imaging Retina, 2015; 46, 56−61. doi:  10.3928/23258160-20150101-09
[14] Xu HP, Chen M, Forrester JV, et al. Cataract surgery induces retinal pro-inflammatory gene expression and protein secretion. Invest Ophthalmol Vis Sci, 2011; 52, 249−55. doi:  10.1167/iovs.10-6001
[15] Chu CJ, Johnston RL, Buscombe C, et al. Risk factors and incidence of macular edema after cataract surgery: a database study of 81984 eyes. Ophthalmology, 2016; 123, 316−23. doi:  10.1016/j.ophtha.2015.10.001
[16] Takkar B. Dexamethasone implant as an effective treatment option for macular edema in Irvine-Gass syndrome. J Cataract Refract Surg, 2016; 42, 648.
[17] Lin CJ, Tsai YY. Use of aflibercept for the management of refractory pseudophakic macular edema in irvine-gass syndrome and literature review. Retin Cases Brief Rep, 2018; 12, 59−62. doi:  10.1097/ICB.0000000000000414
[18] Peng L, Wu PP, Yan B. Intravitreal lucentis combined with triamcinolone acetonide for the treatment of cystoid macular edema in Irvine-Gass syndrome: a case report. Chin J Optome Ophthalmol Vis Sci, 2020; 22, 714−6. (In Chinese
[19] Rhee DJ, Peck RE, Belmont J, et al. Intraocular pressure alterations following intravitreal triamcinolone acetonide. Br J Ophthalmol, 2006; 90, 999−1003. doi:  10.1136/bjo.2006.090340
[20] Al Zamil WM. Short-term safety and efficacy of intravitreal 0.7-mg dexamethasone implants for pseudophakic cystoid macular edema. Saudi J Ophthalmol, 2015; 29, 130−4. doi:  10.1016/j.sjopt.2014.10.005
[21] Meyer LM, Schönfeld CL. Cystoid macular edema after complicated cataract surgery resolved by an intravitreal dexamethasone 0.7-mg implant. Case Rep Ophthalmol, 2011; 2, 319−22. doi:  10.1159/000332424
[22] Brynskov T, Laugesen CS, Halborg J, et al. Longstanding refractory pseudophakic cystoid macular edema resolved using intravitreal 0.7 mg dexamethasone implants. Clin Ophthalmol, 2013; 7, 1171−4.
[23] Errera MH. Dexamethason implant versus posterior sub-tenon triamcinolone acetonide for treatment of macular edema and/or vitritis in intraocular inflammatory diseases. Retrospective cases-series. Acta Ophthalmol, 2014; 92, 1−3.
[24] Medeiros MD, Postorino M, Navarro R, et al. Dexamethasone intravitreal implant for treatment of patients with persistent diabetic macular edema. Ophthalmologica, 2014; 231, 141−6. doi:  10.1159/000356413
[25] Sharma A, Bandello F, Loewenstein A, et al. Current role of intravitreal injections in Irvine Gass syndrome-CRIIG study. Int Ophthalmol, 2020; 40, 3067−75. doi:  10.1007/s10792-020-01491-5
[26] Williams GA, Haller JA, Kuppermann BD, et al. Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol, 2009; 147, 1048−54. e2. doi:  10.1016/j.ajo.2008.12.033